List of Excipients in API olmesartan medoxomil-hydrochlorothiazide
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing olmesartan medoxomil-hydrochlorothiazide
Excipients in ANDA-approved (generic) drugs containing olmesartan medoxomil-hydrochlorothiazide
Detailed excipient profiles for olmesartan medoxomil-hydrochlorothiazide
Excipient focus: CELLULOSE, MICROCRYSTALLINE
olmesartan medoxomil-hydrochlorothiazide drug variants containing CELLULOSE, MICROCRYSTALLINE
olmesartan medoxomil-hydrochlorothiazide drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE RED
olmesartan medoxomil-hydrochlorothiazide drug variants containing FERRIC OXIDE RED
olmesartan medoxomil-hydrochlorothiazide drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERRIC OXIDE YELLOW
olmesartan medoxomil-hydrochlorothiazide drug variants containing FERRIC OXIDE YELLOW
olmesartan medoxomil-hydrochlorothiazide drug variants not containing FERRIC OXIDE YELLOW
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYDROXYPROPYL CELLULOSE
olmesartan medoxomil-hydrochlorothiazide drug variants containing HYDROXYPROPYL CELLULOSE
olmesartan medoxomil-hydrochlorothiazide drug variants not containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE
olmesartan medoxomil-hydrochlorothiazide drug variants containing HYPROMELLOSE
olmesartan medoxomil-hydrochlorothiazide drug variants not containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| Novadoz Pharmaceuticals LLC | olmesartan medoxomil-hydrochlorothiazide | 72205-147 |
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE 2910
olmesartan medoxomil-hydrochlorothiazide drug variants containing HYPROMELLOSE 2910
| Company | Ingredient | NDC |
|---|---|---|
| Novadoz Pharmaceuticals LLC | olmesartan medoxomil-hydrochlorothiazide | 72205-147 |
| >Company | >Ingredient | >NDC |
olmesartan medoxomil-hydrochlorothiazide drug variants not containing HYPROMELLOSE 2910
Excipient focus: LACTOSE MONOHYDRATE
olmesartan medoxomil-hydrochlorothiazide drug variants containing LACTOSE MONOHYDRATE
olmesartan medoxomil-hydrochlorothiazide drug variants not containing LACTOSE MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE
olmesartan medoxomil-hydrochlorothiazide drug variants containing LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE
olmesartan medoxomil-hydrochlorothiazide drug variants not containing LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
olmesartan medoxomil-hydrochlorothiazide drug variants containing MAGNESIUM STEARATE
olmesartan medoxomil-hydrochlorothiazide drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Novadoz Pharmaceuticals LLC | olmesartan medoxomil-hydrochlorothiazide | 72205-147 |
| >Company | >Ingredient | >NDC |
Excipient focus: STEARIC ACID
olmesartan medoxomil-hydrochlorothiazide drug variants containing STEARIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| Novadoz Pharmaceuticals LLC | olmesartan medoxomil-hydrochlorothiazide | 72205-147 |
| >Company | >Ingredient | >NDC |
olmesartan medoxomil-hydrochlorothiazide drug variants not containing STEARIC ACID
Excipient focus: TALC
olmesartan medoxomil-hydrochlorothiazide drug variants containing TALC
olmesartan medoxomil-hydrochlorothiazide drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
olmesartan medoxomil-hydrochlorothiazide drug variants containing TITANIUM DIOXIDE
olmesartan medoxomil-hydrochlorothiazide drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch